


Sema3C Promotes the Survival and Tumorigenicity of Glioma Stem Cells through Rac1 Activation

Graphical Abstract



Authors

Jianghong Man, Jocelyn Shoemake, ..., Jeremy N. Rich, Jennifer S. Yu

Correspondence

yuj2@ccf.org

In Brief

Glioma stem cells (GSCs) have a high capacity for self-renewal, invasion, and survival. How they communicate with each other to survive and maintain their identity is not clear. Man et al. now show that GSCs have co-opted a neurodevelopmental program to activate Rac1 to promote defining features of GSCs.

Highlights

Sema3C and its receptors PlexinA2/PlexinD1 are coordinately expressed in GSCs

GSCs, but not NPCs or NSTCs, secrete and utilize Sema3C to promote their growth

Disruption of Sema3C kills GSCs but spares NPCs by abrogating Rac1 activation

Rac1 activity is vital for ensuring the survival of GSCs, but not NSTCs



Sema3C Promotes the Survival and Tumorigenicity of Glioma Stem Cells through Rac1 Activation

Jianghong Man,¹ Jocelyn Shoemake,¹ Wenchao Zhou,¹ Xiaoguang Fang,¹ Qiulian Wu,¹ Anthony Rizzo,¹ Richard Prayson,^{2,3} Shideng Bao,^{1,3} Jeremy N. Rich,^{1,3} and Jennifer S. Yu^{1,3,4,*}

¹Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute

²Department of Anatomic Pathology, Tomsich Pathology and Laboratory Medicine Institute

³Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute

⁴Department of Radiation Oncology, Taussig Cancer Institute
Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

*Correspondence: yuj2@ccf.org

<http://dx.doi.org/10.1016/j.celrep.2014.10.055>

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

SUMMARY

Different cancer cell compartments often communicate through soluble factors to facilitate tumor growth. Glioma stem cells (GSCs) are a subset of tumor cells that resist standard therapy to contribute to disease progression. How GSCs employ a distinct secretory program to communicate with and nurture each other over the nonstem tumor cell (NSTC) population is not well defined. Here, we show that GSCs preferentially secrete Sema3C and coordinately express PlexinA2/D1 receptors to activate Rac1/nuclear factor (NF)- κ B signaling in an autocrine/paracrine loop to promote their own survival. Importantly, Sema3C is not expressed in neural progenitor cells (NPCs) or NSTCs. Disruption of Sema3C induced apoptosis of GSCs, but not NPCs or NSTCs, and suppressed tumor growth in orthotopic models of glioblastoma. Introduction of activated Rac1 rescued the Sema3C knockdown phenotype *in vivo*. Our study supports the targeting of Sema3C to break this GSC-specific autocrine/paracrine loop in order to improve glioblastoma treatment, potentially with a high therapeutic index.

INTRODUCTION

Glioblastoma (GBM) is a highly infiltrative and incurable primary brain tumor. Despite aggressive therapy, patients with GBM have a dismal prognosis with median survival of about 1 year (Stupp et al., 2009). Tumor control is short lived, with the vast majority of patients progressing within 6 months of diagnosis (Stupp et al., 2009). Glioma stem cells (GSCs) contribute to this resistance because they can efficiently repair DNA damage and activate prosurvival pathways after cytotoxic therapy (Bao et al., 2006; Bleau et al., 2009; Chen et al., 2012; Eramo et al., 2006). GSCs and neural progenitor cells (NPCs) share many common properties including the ability to self-renew and establish a cellular hierarchy; however, the molecular mechanisms un-

derlying these processes may differ. Strategies that exploit the differences between GSC and NPC biology would improve the therapeutic index and minimize potential side effects.

GSCs reside in stem cell niches where they integrate extracellular signals including niche-related factors such as VEGF, cell adhesion molecules, and extracellular matrix components to support their growth and promote angiogenesis (Rosen and Jordan, 2009; Soeda et al., 2009; Vescovi et al., 2006; Zhou et al., 2009). Whereas crosstalk between GSCs and endothelial cells has been demonstrated (Calabrese et al., 2007; Lu et al., 2012; Zhu et al., 2011), the signaling mechanisms GSCs employ to communicate with each other and promote their own survival within the greater nonstem tumor cell (NSTC) population is not well understood. Recent studies reveal that cancer stem-like cells (CSCs) may produce and utilize autocrine or paracrine factors to protect themselves from differentiation and apoptosis (Scheel et al., 2011). In GBM, autocrine transforming growth factor β (TGF β), VEGF, and HGF/cMET signaling play important roles in the maintenance of GSC identity and tumorigenicity (Hamerlik et al., 2012; Ikushima et al., 2009; Joo et al., 2012). However, these pathways also play critical roles in normal physiology. Identification of molecular mechanisms that discriminate between normal and pathologic stem cell survival are essential.

To determine potential therapeutic targets that are differentially expressed by GSCs, we assessed the expression of secreted proteins that have been implicated in cancer. Class 3 semaphorins were initially identified as evolutionarily conserved axon guidance cues that instruct the assembly of the neural circuitry (Tran et al., 2009). Since their discovery, various class 3 semaphorins have been found to influence cancer growth, either positively or negatively depending on tumor type (Neufeld and Kessler, 2008; Tamagnone, 2012; Zhou et al., 2008). Sema3C stands out because it has consistently been shown to promote tumor progression and correlate with poor prognosis across multiple tumor types (Blanc et al., 2011; Esselens et al., 2010; Galani et al., 2002; Herman and Meadows, 2007; Miyato et al., 2012). Sema3C is overexpressed in malignant glioma cell lines (Rieger et al., 2003) and is amplified in GBM (Brennan et al., 2013). However, the expression and function of Sema3C and its receptors in CSCs and GBM remain unknown.




Figure 1. Sema3C and Its Receptors Are Coexpressed in Stem Cell Marker+ GBM Cells

(A and B) Immunohistochemical (IHC) staining of Sema3C, PlexinA2, and PlexinD1 in serial sections of human GBM tissue array. Sections were counterstained with hematoxylin. Asterisk denotes vessel lumen.

(C) Immunofluorescent (IF) staining of Sema3C (red) in relation to blood vessels marked by CD31 staining for endothelial cells (green) in human primary GBM tissues. * denotes vessel lumen.

(legend continued on next page)

Neuropilins and plexins form a receptor complex for semaphorins. Neuropilins serve as the primary receptor for ligand binding, whereas plexins coreceptors transduce semaphorin signaling via their intracellular domain (Capparuccia and Tamagnone, 2009; Hota and Buck, 2012). The plexin intracellular domain interacts with the Rac1 guanosine triphosphatase (GTPase) to promote cell migration (Hota and Buck, 2012). The role of Rac1 in cancer has been underscored by its high frequency of activating mutations in melanoma (Hodis et al., 2012; Krauthammer et al., 2012) and dysregulation in colon (Esufali et al., 2007) and lung cancers (Zhou et al., 2013). Whereas Rac1 is best known for its role in cytoskeletal organization, cell motility, and growth, Rac1 also plays a role in cancer cell survival (Feng et al., 2011; Heasman and Ridley, 2008; Senger et al., 2002). In addition, Rac1 has been implicated in regulating cancer stem cell proliferation (Akunuru et al., 2011; Myant et al., 2013). However, the functional role of semaphorin signaling in regulating Rac1 activity in GBM and, in particular, in GSCs is unclear. In this study, we sought to investigate the role of *Sema3C* and its potential regulation of Rac1 in mediating GSC self-renewal and GBM growth.

RESULTS

Sema3C and Its Receptors *PlexinA2/PlexinD1* Are Differentially Expressed in GSCs

Sema3C is overexpressed in malignant glioma cell lines and amplified in GBM (Brennan et al., 2013; Rieger et al., 2003). However, its role in the pathogenesis of GBM is unclear. We first examined *Sema3C* expression in a panel of human GBM. *Sema3C* staining was strong in a subpopulation of GBM cells from seven different patient specimens compared to normal human brain tissue (Figure S1A). Using a GBM tissue microarray, *Sema3C* was overexpressed in a subpopulation of tumor cells in 30 of 35 (85.7%) GBM but was barely detectable in normal brain (Figure 1A). *Sema3C* binds to the receptors *PlexinA2* and *PlexinD1* (Gitler et al., 2004; Kodo et al., 2009; Law and Lee, 2012). In serial sections, *Sema3C* and *PlexinA2/PlexinD1* expression was highly concordant (Figure 1B), with *PlexinA2* expressed in 90% (32/35) GBM and *PlexinD1* in all 35 GBM. Within normal brain, *Sema3C* staining was weak, but its receptors stained strongly (Figures 1B and S1A). Notably, histoscore analysis showed that *Sema3C* levels were higher in GBM compared to normal brain and correlated with expression of *PlexinA2* ($p < 0.0001$) and *PlexinD1* ($p < 0.0001$; Figures 1D, 1E, and S1B).

To investigate further the expression of *Sema3C* and its receptors, we performed coimmunofluorescence staining on human GBM specimens. Cells that expressed both *Sema3C* and *PlexinA2/PlexinD1* clustered together, suggesting that they may participate in autocrine or paracrine signaling (Figures 1F and 1I). *Sema3C* and *PlexinA2/PlexinD1* were coexpressed with GSC markers including CD133, Olig2, and Sox2 (Singh et al.,

2004; Suvà et al., 2014; Figures 1G–1I, S1C, and S1D). A subset of *Sema3C*-positive cells localized to perivascular niches (Figures 1A, 1C, and S1E), where GSCs are commonly found (Calabrese et al., 2007). These findings suggest that *Sema3C* is coexpressed with its receptors in GSCs.

We next assessed the expression of *Sema3C* and *PlexinA2/PlexinD1* in matched GSCs and NSTCs isolated from fresh GBM patient specimens that were propagated as xenografts and functionally validated (Cheng et al., 2013). *Sema3C* and *PlexinA2/PlexinD1* were elevated in all seven GSC populations enriched for the stem cell markers CD133, Olig2, and Sox2 relative to matched NSTCs (Figures 2A and S2A). The semaphorin ligand-binding receptor (Neufeld and Kessler, 2008; Tamagnone, 2012; Zhou et al., 2008) Neuropilin1 (NRP1), but not NRP2, was ubiquitously expressed in both GSCs and NSTCs (Figure S2B). Of note, expression of other class 3 semaphorins, including *Sema3A* and *Sema3B*, was similar between GSCs and NSTCs (Figure S2C). To rule out the possibility that these patterns of expression were driven by cell culture conditions, we confirmed our analysis using freshly sorted GBM xenografts (Figure 2B). We further validated these results *in situ* by coimmunofluorescence staining of GSC tumorspheres (Figure S2D), GSC-derived GBM xenografts (Figures 2C and S2E–S2I), and fresh GBM patient specimens (Figures 1F–1I). Furthermore, induction of differentiation in GSCs by serum stimulation led to rapid loss of expression of *Sema3C* and its receptors (Figure 2D), suggesting a role for *Sema3C* signaling in GSCs.

Because GSCs and NPCs share several properties, we examined the expression of *Sema3C* and its receptors in normal brain. Oncomine database analysis revealed reduced mRNA levels of *Sema3C* in human NPCs compared to GBM (Figure S2J). NPCs reside in the subventricular zone (SVZ) (Fuentealba et al., 2012; Shen et al., 2008). *PlexinA2* and *PlexinD1* were both expressed in a subpopulation of cells within the SVZ of mouse brain, an area enriched with Sox2-positive cells. *Sema3C*, in contrast, was undetectable within the SVZ (Figures 2E and S2K). Next, we compared expression of *Sema3C* and its receptors in four human NPCs and four pairs of matched GSCs and NSTCs. Consistent with our *in situ* studies (Figure 1), high levels of *Sema3C* and its receptors were found in all four GSCs, but not in NSTCs. *Sema3C* was undetectable in NPCs, but its receptors were expressed at high levels (Figures 2F and S2L). These results collectively reveal that GSCs preferentially coexpress *Sema3C* and its receptors *PlexinA2/PlexinD1* compared to normal brain progenitor cells and nonstem GBM cells.

Secreted *Sema3C* Promotes GSC Survival and Self-Renewal through *PlexinA2/PlexinD1*

To explore the functional roles of *Sema3C* signaling in GSCs, we first investigated the effect of *Sema3C* knockdown on GSC proliferation and tumorsphere formation using two different,

(D and E) Histoscores (D) and correlation analysis (E) of human GBM tissue array stained for *Sema3C*, *PlexinA2*, and *PlexinD1*. * $p < 0.05$; *** $p < 0.001$. NS, not significant.

(F) IF staining of *Sema3C* and *PlexinA2/PlexinD1* on frozen sections of human primary GBM. Nuclei were counterstained with DAPI (blue).

(G–I) IF staining of *Sema3C*, *PlexinA2/PlexinD1*, and GSC markers CD133 and Olig2 on frozen sections of human primary GBM. Nuclei were counterstained with DAPI (blue).

See also Figure S1.




Figure 2. GSCs Preferentially Coexpress Sema3C and Its Receptors

(A) Immunoblot (IB) analysis of Sema3C, PlexinA2, and PlexinD1 in GSCs and matched NSTCs derived from human GBM.
 (B) IB analysis of Sema3C, PlexinA2, and PlexinD1 proteins in GSCs compared to NSTCs isolated via CD133-based sorting from T4302, T3565, and GBM10 xenograft tumors without intervening *in vitro* culture.
 (C) IF staining of Sema3C, PlexinA2, PlexinD1, and GSC markers CD133 and Sox2 on frozen sections of T4302 GSC-derived GBM xenografts. Nuclei were counterstained with DAPI (blue).
 (D) GSC differentiation was induced by serum (5% fetal bovine serum). IB analysis of Sema3C, PlexinA2, PlexinD1, Sox2, and GFAP (astrocyte marker) proteins during GSC differentiation (left). IF staining of Sema3C (red) and GFAP (green) from day 0 to day 5 during GSC differentiation (right). Nuclei were counterstained with DAPI (blue).
 (E) IF staining of Sema3C, PlexinA2, PlexinD1, or Sox2 in the subventricular zone (SVZ) in adult mouse brain. Sections were counterstained with DAPI. * denotes ventricle.
 (F) IB analysis of Sema3C, PlexinA2, and PlexinD1 proteins in four GSCs, matched NSTCs, and four human NPC lines.
 See also Figure S2.




Figure 3. GSC Viability and Self-Renewal Depend on Sema3C Secretion

(A–D) Effects of Sema3C knockdown with two different shRNA sequences on cell viability in GSCs and NPCs and tumosphere formation of GSCs. Knockdown of Sema3C resulted in a decrease in cell viability in GSCs (A), but not in NPCs (B). shSema3C-GSCs showed reduced tumosphere numbers (C). For the limiting dilution assay, GSCs expressing shNT or shSema3C were plated into 96-well plates with various seeding densities (1–200 cells per well, 12 wells per each condition). Seven days later, each well was evaluated for the presence or absence of tumospheres (D). (E–H) Effects of PlexinA2 or PlexinD1 knockdown with two different shRNA sequences on cell viability of GSCs (E and G) and NPCs (F and H).

(legend continued on next page)

nonoverlapping *Sema3C* small hairpin RNA (shRNA) sequences or control nontargeting (NT) shRNA. Reduction of *Sema3C* significantly decreased cell viability in all three GSC populations examined (Figures 3A, S3A, and S3B) but had little effect on matched NSTCs (Figures S3C, S3D, and S3L). In addition, *Sema3C* knockdown impaired GSC self-renewal as assessed by tumorsphere formation and in vitro limiting dilution assay (Figures 3C, 3D, and S3E–S3H), the standard in vitro assay to assess self-renewal capacity (Pastrana et al., 2011). Moreover, knockdown of *Sema3C* did not impact expression of stem cell transcription factors Sox2 or Olig2 in GSCs (Figure 6A), suggesting that it does not alter stem cell identity but rather GSC survival (Figure 5).

Reduction of PlexinA2 or PlexinD1 similarly decreased GSC viability and self-renewal (Figures 3E, 3G, S3I, and S3J) but had little effect on NSTCs (Figure S3L). shRNA-resistant mutants of *Sema3C* or PlexinA2/PlexinD1 rescued cell survival that was reduced by knockdown of these genes (Figure S3M), supporting the specificity of these target shRNAs. To rule out the effects of different culture conditions on the specificity of *Sema3C* for GSCs over NSTCs, we performed a mixing experiment with matched GSCs and NSTCs that were differentially labeled with red fluorescent protein (RFP) or GFP proteins, respectively. The GSCs and NSTCs were plated at a 1:1 ratio together and transduced with *Sema3C* shRNA or NT shRNA. *Sema3C* knockdown strongly inhibited growth of RFP-GSCs, but not GFP-NSTCs (Figure 3I), revealing that *Sema3C* preferentially supports GSCs.

An important attribute for a potential therapeutic target is its differential effects on tumor growth and normal physiology. Importantly, functional studies revealed that *Sema3C* knockdown had no significant impact on NPC growth (Figure 3B). In contrast, knockdown of either PlexinA2 or PlexinD1 resulted in rapid NPC death (Figures 3F and 3H). These data indicate that, for patients with GBM, anti-*Sema3C* therapy may spare NPCs and therefore have limited brain toxicity.

These functional studies complement our expression studies and suggest a role for autocrine or paracrine *Sema3C* signaling in promoting the survival of GSCs specifically. To test this possibility, we performed a mixing experiment in which GSCs transduced with sh*Sema3C* were cultured alone or cocultured with healthy GSCs at a 1:1 ratio. These populations were differentially labeled with GFP (GFP-GSC-sh*Sema3C*) or RFP (RFP-GSC). When cultured in the absence of *Sema3C*-expressing cells (RFP-GSC), cells with reduced *Sema3C* (GFP-GSC-sh*Sema3C*) readily died. In contrast, when these cells were cocultured with *Sema3C*-expressing cells (RFP-GSC), they survived and formed tumorspheres (Figure S3N), suggesting that

secretion of *Sema3C* from the RFP-GSC population could support the survival of GSCs in which *Sema3C* was abrogated.

To determine the dependency of this effect on soluble factors, we performed another coculture experiment in which RFP-GSCs were cultured in an upper chamber and GFP-GSCs transduced with *Sema3C*, PlexinA2, or PlexinD1 shRNA were plated in the lower chamber (Figure 3J). The upper and lower chambers were separated by a permeable membrane that permitted the diffusion of small proteins, but not migration of cells. Coculture of RFP-GSCs rescued the sphere-forming ability of GSCs in which *Sema3C* was knocked down, but not GSCs, in which PlexinA2 or PlexinD1 were knocked down (Figure 3J). These results suggest that secretion of a soluble protein by RFP-GSCs acts through PlexinA2/PlexinD1 to support tumorsphere formation.

We next tested the ability of exogenous recombinant human *Sema3C* to rescue the viability and self-renewal capacity of GSCs in which *Sema3C*, PlexinA2, PlexinD1, or NRP1 were reduced. Exogenous *Sema3C* treatment rescued cell viability and tumorsphere formation in a dose-dependent manner in GSCs with reduced *Sema3C* but had no appreciable effect on GSCs with reduced PlexinA2, PlexinD1, or NRP1 expression (Figures 3K, 3L, S3O, and S3P). Additional exogenous *Sema3C* slightly increased GSC viability and was not utilized by NSTCs (Figures S3Q and S3R). These results revealed that *Sema3C* secretion by GSCs acts through both PlexinA2/PlexinD1 and NRP1 receptors to mediate GSC self-renewal and sphere-forming capacity.

Our studies suggest that NPCs are sensitive to PlexinA2/PlexinD1 knockdown, but not *Sema3C* knockdown. We hypothesized that other semaphorin ligands might engage these receptors to mediate NPC survival. We interrogated a murine brain in situ hybridization database (Allen Institute Brain Atlas database; <http://mouse.brain-map.org>) and found that *Sema4A* and *Sema6A*, the other known ligands of PlexinD1 and PlexinA2, respectively (Neufeld and Kessler, 2008; Zhou et al., 2008), are highly expressed in normal brain during mouse development (Figure S3S). We further validated their expression by western blot in NPCs, GSCs, and NSTCs (Figure S3T). Functional studies revealed that knockdown of *Sema4A* or *Sema6A* significantly inhibited NPC viability but had only limited effect on GSCs (Figure S3U). These results suggest that GSCs and NPCs might utilize different semaphorin ligands to mediate cell survival.

Sema3C Knockdown Reduces Tumor Growth and Improves Animal Survival

To determine the functional consequences of *Sema3C* knockdown in vivo, we established orthotopic xenografts utilizing

(I) GSCs and matched NSTCs stably expressing RFP or GFP were mixed and plated on stem cell Matrigel-coated plates at 1:1 ratio and infected by lentivirus containing shNT or sh*Sema3C*. RFP-GSC or GFP-NSTC were counted at indicated times after infection (right). Representative images of mixed cells on day 0 and day 3 are shown (left).

(J) GFP-GSCs transduced with shNT, sh*Sema3C*, shPlexinA2, or shPlexinD1 were plated at low cell density (500 cells) at the base of transwells and cocultured with RFP-GSCs (1×10^5 cells) that were seeded in the upper chambers of transwells. GFP-GSC tumorsphere number was counted on day 6 of coculture (right). Representative diagram of the coculture assay is shown (left).

(K and L) GSCs transduced with shNT, sh*Sema3C*, shPlexinA2, or shPlexinD1 were cultured with different doses of recombinant human *Sema3C* protein (*Sema3C*-Fc). GSC tumorsphere quantification is shown (K), and GSC viability was assessed by cell titer assay (L).

Data are means \pm SD ($n = 3$). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. See also Figure S3.




Figure 4. Targeting Sema3C Suppresses GSC-Mediated Tumor Growth and Improves Animal Survival

GSCs transduced with shNT or shSema3C through lentiviral infection were intracranially transplanted into the brains of immunocompromised athymic nude mice (2×10^4 cells per mouse). Mouse brains implanted with GSCs were harvested simultaneously to examine the impact of Sema3C disruption on GBM tumor growth (A–F). In the animal survival experiments (G and H), mice implanted with GSCs expressing shNT or shSema3C were maintained until the development of neurological signs or for 180 days, whichever came first.

(A) Representative images of cross-sections (hematoxylin and eosin stained) of mouse brains 25 days after transplantation. Arrow indicates a tumor formed from GSCs expressing shNT.

(legend continued on next page)

shNT or shSema3C-expressing GSCs (shNT mice or shSema3C mice, respectively). Using two different GSC populations, shNT mice readily established intracranial tumors, whereas shSema3C mice demonstrated significantly impaired tumor formation, diminished tumor invasion, and increased survival (Figure 4). When the first few shNT mice developed neurologic signs or clinically declined, a subset of mice in each group was sacrificed. shNT mice developed highly invasive tumors that extended to both hemispheres and exerted significant mass effect. In contrast, shSema3C mice had no clinical signs of tumor growth and only small nests of tumor cells were identified (Figures 4A, 4B, and S4A). Sema3C was strongly expressed in a subpopulation of tumor cells in shNT mice but was undetectable in shSema3C mice (Figures 4C and S4A, bottom). Of note, within shNT mice, a subset of cells expressing high levels of Sema3C localized to the invasive fingers of the tumor (Figure 4D), consistent with a role for Sema3C in facilitating cell invasion (Herman and Meadows, 2007; Miyato et al., 2012). These results are consistent with in vitro Boyden chamber migration assays (Figures S4B and S4C). Using two different orthotopic tumor models, Sema3C knockdown consistently impaired tumor growth, as shown by quantitative bioluminescent imaging, and significantly extended animal survival (Figures 4E–4H). In three of the four Sema3C knockdown tumor models, median survival was not reached by the conclusion of the observation period of 6 months posttransplantation (Figures 4G and 4H).

To further evaluate whether the expression of Sema3C and its receptors in GBM correlated with patient survival, we queried the Oncomine database and found that high expression levels of Sema3C or its receptors PlexinA2 or PlexinD1 in human glioma inversely correlated with patient survival (Figures S4D–S4F). Together, these data suggest that Sema3C instructs the tumorigenic capacity and invasive phenotype of GSCs.

Sema3C Depletion Induces Apoptosis of GSCs, but Not NPCs

A significant increase in cell death was observed after silencing of Sema3C and PlexinA2/PlexinD1 expression in GSCs in cell culture (Figure S5A). These findings raised the possibility that abrogation of Sema3C signaling may induce apoptosis of GSCs. Sema3C knockdown in GSCs increased apoptosis as assessed by annexin V/phosphatidylinositol (PI) flow cytometry (Figure S5B) and TUNEL assay (Figures S5C–S5E). Similarly, knockdown of Sema3C and PlexinA2/PlexinD1 increased levels of cleaved caspase3/caspase7, cleaved poly-ADP ribose polymerase (PARP), and the fraction of TUNEL-positive cells in GSCs, but not in matched NSTCs (Figures 5A–5C, S5F, and S5G). In NPCs, Sema3C knockdown showed no significant effect on these measures of apoptosis (Figures 5B, 5D, and S5H). In contrast, PlexinA2/PlexinD1 knockdown in NPCs effi-

ciently increased apoptosis (Figures 5B, 5D, S5G, and S5H). Consistent with our in vitro findings, GBM tissue from shSema3C mice showed significantly elevated levels of apoptotic TUNEL-positive and cleaved-caspase-3-positive tumor cells (Figures 5E–5G). These data support that Sema3C suppresses apoptosis of GSCs, but not NSTCs or NPCs.

Sema3C Activates Rac1 to Mediate Survival of GSCs

To further understand a mechanism by which Sema3C protects GSCs from apoptosis, we investigated the interaction between Sema3C and its receptors PlexinA2/PlexinD1 and NRP1. Sema3C coimmunoprecipitated with PlexinA2, PlexinD1, or NRP1 (Figures S6A and S6B, up). The receptors themselves interacted with each other (Figures S6A and S6B, up), and knockdown of NRP1 abrogated the interaction with Sema3C and PlexinA2/PlexinD1 (Figure S6B, down). These results suggest that Sema3C, PlexinA2/PlexinD1, and NRP1 might form a complex in GSCs, with NRP1 functioning as the ligand-binding receptor. Plexins can engage many signaling pathways including Ras, Akt, and Rac pathways (Neufeld and Kessler, 2008). Using a candidate approach, Sema3C knockdown significantly decreased GTP-bound, active Rac1 in GSCs but had little effect on ERK or Akt activation. In NPCs, however, activated Rac1 levels were unchanged after Sema3C knockdown (Figure 6A). In addition, phospho-kinase array analysis showed that Sema3C had no significant effects on p38 mitogen-activated protein kinase (MAPK), JNK, p53, or STAT signaling (data not shown).

Rac1 is known to interact with the intracellular domain of plexins (Hota and Buck, 2012). To determine the role of plexins in transducing Sema3C signals, we knocked down PlexinA2 or PlexinD1 in GSCs and assessed activation of Rac1. Knockdown of either PlexinA2 or PlexinD1 inhibited Rac1 activity (Figure 6B). Furthermore, treatment of control GSCs with recombinant human Sema3C increased activated Rac1 levels in a dose-dependent manner but had minimal effect on GSCs with reduced PlexinA2/PlexinD1 (Figure 6B). PlexinA2/PlexinD1 mutants lacking the intracellular domain failed to rescue tumorsphere formation in GSCs in which PlexinA2/PlexinD1 were knocked down (data not shown). Together, these findings demonstrate that Sema3C engages the PlexinA2/PlexinD1 receptor complex to regulate Rac1 activation in GSCs, but not NPCs.

GSCs Exhibit Increased Sensitivity to Rac1 Inhibition

Rac1 has been implicated in cancer cell survival (Senger et al., 2002; Velaitan et al., 2011), but its role in cancer stem cells is not well established. Inhibition of Rac1 by the pharmacologic inhibitor NSC23766 or knockdown approaches strongly inhibited GSC viability, reduced tumorsphere formation, and induced apoptosis of GSCs (Figures 6C–6F and S6C–S6F), revealing that

(B) Histological analysis of brain tumors derived from GSCs expressing shNT or shSema3C. H&E, hematoxylin and eosin.

(C and D) IHC staining of Sema3C in GBM xenografts derived from GSCs expressing shNT or shSema3C. Staining at the center (C) or periphery (D) of shNT mouse tumors is shown. Sections were counterstained with hematoxylin. Arrows indicate Sema3C-positive cells.

(E and F) GBM xenografts derived from luciferase-labeled GSCs expressing shNT or shSema3C were tracked by bioluminescence (right). Real-time images from animals on day 25 (E) and 33 (F) are shown (left). Error bars represent the mean \pm SEM.

(G and H) Kaplan-Meier survival curves of mice implanted with 08-387 GSCs (G) and T3691 GSCs (H) expressing shNT or shSema3C.

p < 0.01; *p < 0.001. See also Figure S4.




Figure 5. Sema3C Depletion Induces Apoptosis of GSCs, but Not NPCs

(A and B) IB analysis of cleaved-caspase3, -caspase7, and -PARP proteins in GSCs and matched NSTCs (A) or GSCs and NPCs (B) in which Sema3C, PlexinA2, or PlexinD1 were knocked down by two separate shRNAs.

(C and D) Apoptotic cells in GSCs (C) or NPCs (D) expressing shNT, shSema3C, shPlexinA2, or shPlexinD1 were detected by TUNEL assay. The apoptotic index was assessed by the ratio of TUNEL-positive cells/total number of cells from eight randomly selected fields.

(E–G) Apoptotic cells in GBM xenografts derived from GSCs expressing shNT or shSema3C were detected in situ using the TUNEL assay (E and F) or cleaved-caspase3 staining (G). The apoptotic index was assessed by the ratio of TUNEL-positive cells or cleaved-caspase3-positive cells/total number of cells from eight randomly selected fields.

Data are means \pm SD (n = 3). **p < 0.01; ***p < 0.001. See also Figure S5.




Figure 6. Sema3C Activates Rac1 to Promote Survival of GSCs

(A) Detection of the GTP-bound form of active Rac1 in a pull-down assay from the lysates of GSCs and NPCs expressing shNT or shSema3C. Cell lysates from the indicated cells were analyzed for protein levels of total Rac1, Sema3C, p-ERK1/p-ERK2, p-Akt1, Sox2, and Olig2.
 (B) GSCs transduced with shNT, shPlexinA2, or shPlexinD1 were cultured with different doses of recombinant human Sema3C protein (r-Sema3C). IB analysis of active GTP-Rac1 by pull-down assay from the lysates of indicated GSCs.
 (C) RFP-GSCs and matched GFP-NSTCs were mixed at a 1:1 ratio, plated on stem cell Matrigel-coated plates, and treated with Rac1 inhibitor NSC23766 (50 μ M). Representative images of mixed cells on day 0 and day 3 (left). Quantification of RFP-GSC and GFP-NSTC cell number 3 days after treatment (right). Data are means \pm SD (n = 3).
 (D) Knockdown of Rac1 with two separate shRNAs resulted in significantly decreased cell viability in GSCs, but not in NSTCs. Data are means \pm SD (n = 3).
 (E) Knockdown of Rac1 via two separate shRNAs resulted in decreased tumorsphere formation. Data are means \pm SD (n = 3).
 (F) IB analysis of cleaved-PARP and -caspase3 in GSCs and matched NSTCs transduced with shNT or two separate shRac1. Active GTP-Rac1 by pull-down assay is shown.
 (G and H) IB analysis of p-p65, p65, CyclinD1, Survivin, XIAP, and BCL2 in two GSCs treated with Rac inhibitor (G) or transduced with shNT or two separate shRac1 (H).

*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S6.

Rac1 signaling is necessary for GSC survival. However, Rac1 inhibition had minimal effects on NSTCs, even though Rac1 activation was comparable between NSTCs and GSCs (Figures 6C–6F and S6C–S6F). Rac1 knockdown significantly increased apoptosis of GSCs but had minimal effect on NSTCs (Figures 6F

and S6F). GSCs are therefore dependent on Rac1 signaling for their survival and are particularly sensitive to Rac1 inhibition.

To determine how Rac1 might regulate GSC survival, we assessed nuclear factor (NF)- κ B signaling, a downstream pathway (Myant et al., 2013) that has been implicated in GBM cell survival.

NF- κ B activation promotes radiation resistance of GSCs and correlates with poor survival (Bhat et al., 2013; Bredel et al., 2011; Park et al., 2009). In two GSC populations, blocking Rac1 activation with a pharmacologic inhibitor or Rac1 shRNA reduced activation of p65/RelA and expression of NF- κ B-dependent target genes, cyclinD1, XIAP, and survivin (Figures 6G and 6H). Collectively, these data demonstrate that Rac1 regulation of NF- κ B is vital for GSCs.

Rac1 Activation Rescues the Phenotype Caused by Sema3C Disruption in GSCs

To further define the role of Rac1 in Sema3C-mediated GSC survival, we introduced constitutively activated Rac1 (Flag-Rac1Q61L), which abolishes GTP hydrolysis and mimics the GTP-bound state (Wu et al., 2009), into GSCs in which Sema3C was knocked down. Ectopic expression of Flag-Rac1Q61L in shSema3C GSCs restored NF- κ B activation, reduced apoptosis (Figure 7A), and rescued GSC proliferation and sphere-forming ability (Figures 7B, 7C, and S7A). Similarly, in vivo, ectopic expression of activated Rac1 significantly accelerated tumor growth and reduced survival of shSema3C mice (Figures 7D, 7E, and S7B). However, expression of activated Rac1 by itself did not significantly alter survival compared to shNT mice (Figure 7E). Ectopic expression of Rac1Q61L increased p65/RelA nuclear staining to rescue Sema3C knockdown in GBM xenografts (Figures 7F and 7G), suggesting that Sema3C regulates NF- κ B activation through Rac1. Both in vitro and in vivo, activated Rac1 restored GSC migration and promoted tumor cell invasion despite Sema3C knockdown (Figures S7C and S7D). Collectively, these data suggest that Sema3C activates Rac1 in GSCs to drive tumor growth and invasion.

DISCUSSION

In this study, we identified an autocrine/paracrine Sema3C-PlexinA2/PlexinD1 loop employed by GSCs to promote their survival and invasion (Figure 7Ha). In GBM, activation of Sema3C-PlexinA2/PlexinD1 signaling appears to be confined to the stem cell compartment. GSCs, but not NSTCs, preferentially express Sema3C and PlexinA2/PlexinD1. GSCs were dependent on Sema3C-PlexinA2/PlexinD1-Rac1 signaling for their survival and were able to utilize exogenous Sema3C. However, NSTCs were unresponsive to recombinant Sema3C, probably because they lacked PlexinA2/PlexinD1 expression. Interestingly, knockdown of Sema3C did not alter the expression of stem cell markers or cause differentiation of GSCs. This suggests that Sema3C regulates the survival of GSCs and contributes to the maintenance of their subpopulation rather than instructing cell-fate decisions. In preclinical models, abrogation of Sema3C significantly impaired tumor growth and invasion and extended animal survival in a Rac1-dependent manner.

GSCs have been implicated in GBM treatment failure because of their self-renewal properties and resistance to standard cytotoxic therapy. GSCs have evolved to co-opt core developmental programs to ensure their survival. Targeting GSCs remains a daunting task due to the many vital signaling pathways shared between cancerous and normal progenitor

cell populations (Gilbertson and Rich, 2007). We therefore sought to identify differences in the regulation of these pathways in GSCs and NPCs.

In contrast to PlexinA2/PlexinD1 receptors, Sema3C was undetectable in cultured NPCs and native NPCs in the subventricular zone. Perturbations of Sema3C in NPCs had minimal functional impact. Intriguingly, knockdown of either PlexinA2 or PlexinD1 receptors was sufficient to induce apoptosis of both GSCs and NPCs (Figure 7Hb). These results suggest that, under different selective pressures, GSCs and NPCs have independently evolved distinct molecular pathways that converge on PlexinA2/PlexinD1 and Rac1 to promote cell survival. We speculate that GSCs have evolved to overexpress and utilize Sema3C, whereas NPCs may engage other semaphorins, such as Sema4A and Sema6A (Figures S3S–S3U), known ligands for PlexinA2/PlexinD1 (Neufeld and Kessler, 2008; Zhou et al., 2008). Thus, these studies suggest that anti-Sema3C strategies may target GSCs and have a favorable therapeutic index.

Secreted proteins are logical therapeutic targets because they are exposed to the microenvironment and obviate the need for a drug to move intracellularly. Ligand sequestration drugs or monoclonal antibodies that block receptors, such as aflibercept (VEGF-Trap) and bevacizumab (Avastin), have been successful in some solid tumors (Lambrechts et al., 2013; Stewart et al., 2012), but not GBM (Gilbert et al., 2013). Our study provides a strong biological rationale for the development of similar types of Sema3C-directed therapies.

Rac1 is best known as a regulator of cell motility (Heasman and Ridley, 2008; Kaibuchi et al., 1999) and has been implicated as a driver of invasion and metastasis in many cancers, including GBM (Chan et al., 2005; Feng et al., 2011). Previous studies have suggested that Sema3C could promote migration and invasion of cancer cells, and its overexpression is associated with poor survival (Herman and Meadows, 2007; Martín-Satué and Blanco, 1999; Miyato et al., 2012). Our data also support a role for Sema3C in stimulating the invasion of GSCs through Rac1 activation. Sema3C-positive cells localized to the invasive nests of GBM, and knockdown of Sema3C reduced migration both in vitro and in mouse models. Reintroduction of constitutively active Rac1 in Sema3C-deficient tumors restored the invasive phenotype. Together, these data demonstrate that Sema3C-mediated activation of Rac1 contributes to the highly invasive phenotype of GSCs.

Our studies also extend the function of Rac1 to the survival of GSCs. Rac1 has been implicated in regulating apoptosis in several types of cancers. In the intestine, Rac1 regulates reactive oxygen species production and NF- κ B to stimulate the hyperproliferation and transformation of LGR5-positive stem cells in the setting of constitutive Wnt signaling (Myant et al., 2013). In hematopoietic cells, Rac1 regulates PI 3-kinase (PI3K)-Akt and p38-MAPK-signaling pathways to promote survival (Nishida et al., 1999) and maintains hematopoietic stem/progenitor cells (Gu et al., 2003). In GSCs, we found that Sema3C can activate Rac1 through PlexinA2/PlexinD1 receptors. Rac1 inhibition by both pharmacologic or shRNA approaches reduced NF- κ B activation and decreased levels of Survivin and XIAP to facilitate apoptosis of GSCs. Furthermore, constitutively active




Figure 7. Ectopic Expression of a Constitutively Active Rac1 in GSCs Rescued the Phenotype Caused by Sema3C Disruption

(A) IB analysis of cleaved-PARP, -caspase3, p-p65, p65, and NF- κ B-dependent gene expression in GSCs transduced with control vector or constitutively active Rac1 (Flag-Rac1Q61L) in combination with shNT or shSema3C.

(B and C) GSCs were treated as described in (A), and cell viability was assessed by cell titer assay (B). Quantification of GSC tumorsphere number is shown (C). Data are means \pm SD (n = 3).

(D and E) GSCs (08-387, labeled with luciferase) were treated as described in (A). Forty-eight hours after infection, GSCs were transplanted into the brains of immunocompromised nonobese diabetic severe combined immunodeficiency gamma mice. GBM xenograft growth was tracked by bioluminescence (D). Error bars represent the mean \pm SEM. Kaplan-Meier survival curves of different groups of mice are shown (E). Mice were maintained until the development of neurological signs.

(F and G) IHC staining of Rac1-GTP and p65 in GBM xenografts derived from GSCs treated as indicated (F). Sections were counterstained with hematoxylin. Histoscore analysis for Rac1-GTP and p65 is shown (G). Data are means \pm SD (n = 3).

(H) Proposed model for Sema3C signaling on the regulation of GSC survival. (a) Sema3C and PlexinA2/PlexinD1 are differentially coexpressed in GSCs, but not NSTCs. GSCs secrete and utilize Sema3C in an autocrine/paracrine loop to promote their survival by facilitating Rac1 signaling. NSTCs do not express or utilize Sema3C. (b) PlexinA2/PlexinD1 are expressed in NPCs and contribute to their survival. NPCs do not express or require Sema3C.

*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S7.

Rac1 rescued the Sema3C knockdown phenotype in mice. Examination of these tumors revealed increased levels of nuclear p65 staining. We did not detect significant regulation of PI3K-Akt or MAPK/ERK signaling by Sema3C or Rac1. These data

suggest that Sema3C-mediated activation of Rac1 and NF- κ B promotes GSC survival and tumorigenicity. Moreover, the dependency of GSCs on Rac1 for their survival is also of therapeutic significance. Our results are timely because a new generation

of Rac1 inhibitors is just beginning to enter clinical trials and could be extended to patients with GBM.

In summary, we have identified Sema3C signaling as a central regulator of GSC survival and GBM progression. Targeting Sema3C will disrupt the GSC-specific autocrine/paracrine signaling loop potentially with limited normal brain toxicity. Our data support Sema3C as a promising therapeutic target for GBM.

EXPERIMENTAL PROCEDURES

Isolation and Culture of GSCs and NPCs

GBM surgical specimens were collected for this study in accordance with a Cleveland-Clinic-Institutional-Review-Board-approved protocol. GSCs and NSTCs were isolated and characterized from GBM surgical specimens or xenografts as previously described (Cheng et al., 2013). For the detailed procedure, please see Supplemental Experimental Procedures.

Immunofluorescence Staining, Immunohistochemistry, and Immunoblot Analysis

Immunofluorescent staining of cells and tissues sections was performed as described (Guryanova et al., 2011). Immunohistochemistry staining of tissue section was performed with an ABC kit using DAB (3,30-diaminobenzine) detection (Vector Lab) as previously described (Guryanova et al., 2011). Immunoblot analysis was performed as previously described (Huang et al., 2011). For the detailed procedure, please see Supplemental Experimental Procedures.

For methods related to differentiation assay, DNA constructs and lentiviral transfection, orthotopic mouse xenografts, necropsy, cell viability assays, TUNEL assay, Rac1 activation assay, and immunoprecipitation, see the Supplemental Experimental Procedures.

Statistical Analysis

All grouped data are presented as mean \pm SD. Difference between groups was assessed by one-way ANOVA or one-way ANOVA on ranks tests. All in vitro experiments were repeated at least three times. For the in vivo experiments, log rank survival analysis was performed. Graphpad Prism was used for all statistical analyses.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2014.10.055>.

AUTHOR CONTRIBUTIONS

J.M. and J.S. performed and analyzed the experiments. W.Z., X.F., Q.W., A.R., and S.B. provided reagents and technical advice. R.P., S.B., and J.N.R. helped provide human specimens, and R.P. helped analyze staining. J.M. and J.S.Y. designed the overall research and wrote the manuscript.

ACKNOWLEDGMENTS

This work was supported by the Amy Post Brain Tumor Foundation, Scott Hamilton CARES Award, Cleveland Clinic Foundation, Clinical and Translational Science Collaborative of Cleveland, KL2TR000440 from the NCATS component of the NIH, and the NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Received: May 7, 2014

Revised: July 30, 2014

Accepted: October 21, 2014

Published: November 20, 2014

REFERENCES

- Akunuru, S., Palumbo, J., Zhai, Q.J., and Zheng, Y. (2011). Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. *PLoS ONE* 6, e16951.
- Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., and Rich, J.N. (2006). Glioma stem cells promote chemoresistance by preferential activation of the DNA damage response. *Nature* 444, 756–760.
- Bhat, K.P., Balasubramanian, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. (2013). Mesenchymal differentiation mediated by NF- κ B promotes radiation resistance in glioblastoma. *Cancer Cell* 24, 331–346.
- Blanc, V., Nariculam, J., Munson, P., Freeman, A., Klocker, H., Masters, J., and Williamson, M. (2011). A role for class 3 semaphorins in prostate cancer. *Prostate* 71, 649–658.
- Bleau, A.M., Hambarzumyan, D., Ozawa, T., Fomchenko, E.I., Huse, J.T., Brennan, C.W., and Holland, E.C. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. *Cell Stem Cell* 4, 226–235.
- Bredel, M., Scholtens, D.M., Yadav, A.K., Alvarez, A.A., Renfrow, J.J., Chandler, J.P., Yu, I.L., Carro, M.S., Dai, F., Tagge, M.J., et al. (2011). NFKBIA deletion in glioblastomas. *N. Engl. J. Med.* 364, 627–637.
- Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Nourbakhsh, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al.; TCGA Research Network (2013). The somatic genomic landscape of glioblastoma. *Cell* 155, 462–477.
- Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y., Gaber, M.W., Finklestein, D., Allen, M., et al. (2007). A perivascular niche for brain tumor stem cells. *Cancer Cell* 11, 69–82.
- Capparruccia, L., and Tamagnone, L. (2009). Semaphorin signaling in cancer cells and in cells of the tumor microenvironment—two sides of a coin. *J. Cell Sci.* 122, 1723–1736.
- Chan, A.Y., Coniglio, S.J., Chuang, Y.Y., Michaelson, D., Knaus, U.G., Philips, M.R., and Symons, M. (2005). Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. *Oncogene* 24, 7821–7829.
- Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada, L.F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* 488, 522–526.
- Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J.K., Fang, X., Sloan, A.E., Mao, Y., Lathia, J.D., et al. (2013). Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. *Cell* 153, 139–152.
- Eramo, A., Ricci-Vitiani, L., Zeuner, A., Pallini, R., Lotti, F., Sette, G., Pilozzi, E., Larocca, L.M., Peschle, C., and De Maria, R. (2006). Chemotherapy resistance of glioblastoma stem cells. *Cell Death Differ.* 13, 1238–1241.
- Esselens, C., Malapeira, J., Colomé, N., Casal, C., Rodríguez-Manzaneque, J.C., Canals, F., and Arribas, J. (2010). The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. *J. Biol. Chem.* 285, 2463–2473.
- Esufali, S., Charames, G.S., Pethe, V.V., Buongiorno, P., and Bapat, B. (2007). Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells. *Cancer Res.* 67, 2469–2479.
- Feng, H., Hu, B., Liu, K.W., Li, Y., Lu, X., Cheng, T., Yiin, J.J., Lu, S., Keezer, S., Fenton, T., et al. (2011). Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFR α -stimulated glioma tumorigenesis in mice and humans. *J. Clin. Invest.* 121, 4670–4684.
- Fuentealba, L.C., Obernier, K., and Alvarez-Buylla, A. (2012). Adult neural stem cells bridge their niche. *Cell Stem Cell* 10, 698–708.
- Galani, E., Sgouros, J., Petropoulou, C., Janinis, J., Aravantinos, G., Dionysiou-Asteriou, D., Skarlos, D., and Gonos, E. (2002). Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings

- and clinical outcome in ovarian and breast cancer patients. *Anticancer Res.* 22, 2275–2280.
- Gilbert, M.R., Wang, M., Aldape, K.D., Stupp, R., Hegi, M.E., Jaeckle, K.A., Armstrong, T.S., Wefel, J.S., Won, M., Blumenthal, D.T., et al. (2013). Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. *J. Clin. Oncol.* 31, 4085–4091.
- Gilbertson, R.J., and Rich, J.N. (2007). Making a tumour's bed: glioblastoma stem cells and the vascular niche. *Nat. Rev. Cancer* 7, 733–736.
- Gitler, A.D., Lu, M.M., and Epstein, J.A. (2004). PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. *Dev. Cell* 7, 107–116.
- Gu, Y., Filippi, M.D., Cancelas, J.A., Siefiring, J.E., Williams, E.P., Jasti, A.C., Harris, C.E., Lee, A.W., Prabhakar, R., Atkinson, S.J., et al. (2003). Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. *Science* 302, 445–449.
- Guryanova, O.A., Wu, Q., Cheng, L., Lathia, J.D., Huang, Z., Yang, J., MacSwords, J., Eyler, C.E., McLendon, R.E., Heddleston, J.M., et al. (2011). Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. *Cancer Cell* 19, 498–511.
- Hamerlik, P., Lathia, J.D., Rasmussen, R., Wu, Q., Bartkova, J., Lee, M., Moudry, P., Bartek, J., Jr., Fischer, W., Lukas, J., et al. (2012). Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. *J. Exp. Med.* 209, 507–520.
- Heasman, S.J., and Ridley, A.J. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies. *Nat. Rev. Mol. Cell Biol.* 9, 690–701.
- Herman, J.G., and Meadows, G.G. (2007). Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. *Int. J. Oncol.* 30, 1231–1238.
- Hodis, E., Watson, I.R., Kryukov, G.V., Arold, S.T., Imielinski, M., Theurillat, J.P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012). A landscape of driver mutations in melanoma. *Cell* 150, 251–263.
- Hota, P.K., and Buck, M. (2012). Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. *Cell. Mol. Life Sci.* 69, 3765–3805.
- Huang, Z., Wu, Q., Guryanova, O.A., Cheng, L., Shou, W., Rich, J.N., and Bao, S. (2011). Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. *Nat. Cell Biol.* 13, 142–152.
- Ikushima, H., Todo, T., Ino, Y., Takahashi, M., Miyazawa, K., and Miyazono, K. (2009). Autocrine TGF- β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. *Cell Stem Cell* 5, 504–514.
- Joo, K.M., Jin, J., Kim, E., Ho Kim, K., Kim, Y., Gu Kang, B., Kang, Y.J., Lathia, J.D., Cheong, K.H., Song, P.H., et al. (2012). MET signaling regulates glioblastoma stem cells. *Cancer Res.* 72, 3828–3838.
- Kaibuchi, K., Kuroda, S., and Amano, M. (1999). Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. *Annu. Rev. Biochem.* 68, 459–486.
- Kodo, K., Nishizawa, T., Furutani, M., Arai, S., Yamamura, E., Joo, K., Takahashi, T., Matsuoka, R., and Yamagishi, H. (2009). GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. *Proc. Natl. Acad. Sci. USA* 106, 13933–13938.
- Krauthammer, M., Kong, Y., Ha, B.H., Evans, P., Bacchicocchi, A., McCusker, J.P., Cheng, E., Davis, M.J., Goh, G., Choi, M., et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat. Genet.* 44, 1006–1014.
- Lambrechts, D., Lenz, H.J., de Haas, S., Carmeliet, P., and Scherer, S.J. (2013). Markers of response for the antiangiogenic agent bevacizumab. *J. Clin. Oncol.* 31, 1219–1230.
- Law, J.W.S., and Lee, A.Y.W. (2012). The role of semaphorins and their receptors in gliomas. *J. Signal Transduct.* 2012, 902854.
- Lu, K.V., Chang, J.P., Parachoniak, C.A., Pandika, M.M., Aghi, M.K., Meyronet, D., Isachenko, N., Fouse, S.D., Phillips, J.J., Cheresch, D.A., et al. (2012). VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. *Cancer Cell* 22, 21–35.
- Martín-Satué, M., and Blanco, J. (1999). Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display. *J. Surg. Oncol.* 72, 18–23.
- Miyato, H., Tsuno, N.H., and Kitayama, J. (2012). Semaphorin 3C is involved in the progression of gastric cancer. *Cancer Sci.* 103, 1961–1966.
- Myant, K.B., Cammareri, P., McGhee, E.J., Ridgway, R.A., Huels, D.J., Cordeiro, J.B., Schwitalla, S., Kalna, G., Ogg, E.L., Athineos, D., et al. (2013). ROS production and NF- κ B activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. *Cell Stem Cell* 12, 761–773.
- Neufeld, G., and Kessler, O. (2008). The semaphorins: versatile regulators of tumor progression and tumour angiogenesis. *Nat. Rev. Cancer* 8, 632–645.
- Nishida, K., Kaziro, Y., and Satoh, T. (1999). Anti-apoptotic function of Rac in hematopoietic cells. *Oncogene* 18, 407–415.
- Park, S., Hatanpaa, K.J., Xie, Y., Mickey, B.E., Madden, C.J., Raisanen, J.M., Ramnarain, D.B., Xiao, G., Saha, D., Boothman, D.A., et al. (2009). The receptor interacting protein 1 inhibits p53 induction through NF- κ B activation and confers a worse prognosis in glioblastoma. *Cancer Res.* 69, 2809–2816.
- Pastrana, E., Silva-Vargas, V., and Doetsch, F. (2011). Eyes wide open: a critical review of sphere-formation as an assay for stem cells. *Cell Stem Cell* 8, 486–498.
- Rieger, J., Wick, W., and Weller, M. (2003). Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. *Glia* 42, 379–389.
- Rosen, J.M., and Jordan, C.T. (2009). The increasing complexity of the cancer stem cell paradigm. *Science* 324, 1670–1673.
- Scheel, C., Eaton, E.N., Li, S.H., Chaffer, C.L., Reinhardt, F., Kah, K.J., Bell, G., Guo, W., Rubin, J., Richardson, A.L., and Weinberg, R.A. (2011). Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. *Cell* 145, 926–940.
- Senger, D.L., Tudan, C., Guiot, M.C., Mazzoni, I.E., Molenkamp, G., LeBlanc, R., Antel, J., Olivier, A., Snipes, G.J., and Kaplan, D.R. (2002). Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. *Cancer Res.* 62, 2131–2140.
- Shen, Q., Wang, Y., Kokovay, E., Lin, G., Chuang, S.M., Goderie, S.K., Roy-sam, B., and Temple, S. (2008). Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. *Cell Stem Cell* 3, 289–300.
- Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating cells. *Nature* 432, 396–401.
- Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R.D., Engh, J., Iwama, T., Kunisada, T., Kassam, A.B., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 α . *Oncogene* 28, 3949–3959.
- Stewart, M.W., Grippone, S., and Kirkpatrick, P. (2012). Aflibercept. *Nat. Rev. Drug Discov.* 11, 269–270.
- Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J., Janzer, R.C., Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K., et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* 10, 459–466.
- Suvà, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin, S.D., Riggi, N., Chi, A.S., Cahill, D.P., Nahed, B.V., et al. (2014). Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell* 157, 580–594.
- Tamagnone, L. (2012). Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. *Cancer Cell* 22, 145–152.

- Tran, T.S., Rubio, M.E., Clem, R.L., Johnson, D., Case, L., Tessier-Lavigne, M., Haganir, R.L., Ginty, D.D., and Kolodkin, A.L. (2009). Secreted semaphorins control spine distribution and morphogenesis in the postnatal CNS. *Nature* **462**, 1065–1069.
- Velaithan, R., Kang, J., Hirpara, J.L., Loh, T., Goh, B.C., Le Bras, M., Brenner, C., Clement, M.V., and Pervaiz, S. (2011). The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity. *Blood* **117**, 6214–6226.
- Vescovi, A.L., Galli, R., and Reynolds, B.A. (2006). Brain tumour stem cells. *Nat. Rev. Cancer* **6**, 425–436.
- Wu, Y.I., Frey, D., Lungu, O.I., Jaehrig, A., Schlichting, I., Kuhlman, B., and Hahn, K.M. (2009). A genetically encoded photoactivatable Rac controls the motility of living cells. *Nature* **461**, 104–108.
- Zhou, Y., Gunput, R.A., and Pasterkamp, R.J. (2008). Semaphorin signaling: progress made and promises ahead. *Trends Biochem. Sci.* **33**, 161–170.
- Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., and Dirks, P.B. (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. *Nat. Rev. Drug Discov.* **8**, 806–823.
- Zhou, C., Licciulli, S., Avila, J.L., Cho, M., Troutman, S., Jiang, P., Kossenkov, A.V., Showe, L.C., Liu, Q., Vachani, A., et al. (2013). The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. *Oncogene* **32**, 903–909.
- Zhu, T.S., Costello, M.A., Talsma, C.E., Flack, C.G., Crowley, J.G., Hamm, L.L., He, X., Hervey-Jumper, S.L., Heth, J.A., Muraszko, K.M., et al. (2011). Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. *Cancer Res.* **71**, 6061–6072.